A comparative study to assess the effect of retreatment with 2 doses of MabThera on disease activity score in patients with active rheumatoid arthritis who have had an inadequate response or intolerance to antiTNF-alfa therapy (SMART)
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SMART
- Sponsors Roche
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 22 Nov 2011 Primary endpoint 'C-reactive-protein' has been met according to 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals.
- 22 Nov 2011 Primary endpoint 'Disease-activity-score' has been met according to 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals.